Application of methyl in drug design

Yaoxue Xuebao

Volumn 48, Issue 8, 2013, Pages 1195-1208

  Lian, Jie ^a,b   Wang, Jiang ^b   Sun, Hai Feng ^b   Lin, Dai Zong ^b   Liu, Hong ^a,b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Drug design; Lead optimization; Liposolubility; Methyl; Stereoelectronic effect

Indexed keywords

DRUG; METHYL GROUP;

CONFORMATION; DRUG DESIGN; DRUG METABOLISM; DRUG STABILITY; MOLECULE; PHYSICAL CHEMISTRY; REVIEW; CHEMICAL PHENOMENA; CHEMISTRY; LIPID METABOLISM; METABOLISM; METHYLATION; SOLUBILITY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

DRUG DESIGN; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPID METABOLISM; METHYLATION; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84883228555     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Barreiro EJ, Kümmerle AE, Fraga CA. The methylation effect in medicinal chemistry [J]. Chem Rev, 2011, 111: 5215-5246.
2. Gierse JK, McDonald JJ, Hauser SD, et al. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors [J]. J Biol Chem, 1996, 271: 15810-15814. (Pubitemid 26225362)
3. Wong E, Bayly C, Waterman HL, et al. Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His(513)->Arg and Ile(523)->Val mutation [J]. J Biol Chem, 1997, 272: 9280-9286. (Pubitemid 27154939)
4. Mannhold R, Rekker RF. The hydrophobic fragmental constant approach for calculating logP in octanol/water and aliphatic hydrocarbon/water systems [J]. Perspect Drug Discov, 2000, 18: 1-18. (Pubitemid 30191020)
5. Ooms F, Wouters J, Oscari O, et al. Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling [J]. J Med Chem, 2002, 45: 1748-1756. (Pubitemid 34415370)
6. Rinaldicarmona M, Barth F, Heaulme M, et al. Sr141716a, a potent and selective antagonist of the brain cannabinoid receptor [J]. FEBS Lett, 1994, 350: 240-244.
7. Rinaldicarmona M, Barth F, Heaulme M, et al. Biochemical and pharmacological characterization of Sr141716a, the first potent and selective brain cannabinoid receptor antagonist [J]. Life Sci, 1995, 56: 1941-1947.
8. Cui JJ, Tran-Dubé M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) [J]. J Med Chem, 2011, 54: 6342-6363.
9. Southall NT, Dill KA, Haymet ADJ. A view of the hydrophobic effect [J]. J Phys Chem B, 2002, 106: 521-533. (Pubitemid 35276170)
10. Ji XJ, Liu XM, Li K, et al. Pharmacological studies of meisoindigo: absorption and mechanism of action [J]. Biomed Environ Sci, 1991, 4: 332-337.
11. Ji XJ, Zhang FR. Studies on antineoplastic action of indirubin derivatives and anologues and their structure-activity relationship [J]. Acta Pharm Sin, 1985, 20: 137-139.
12. Hill SJ, Ganellin CR, Timmerman H, et al. International union of pharmacology. XIII. Classification of histamine receptors [J]. Pharmacol Rev, 1997, 49: 253-278. (Pubitemid 27414915)
13. Ganellin R. 1980 award in medicinal chemistry - medicinal chemistry and dynamic structure-activity analysis in the discovery of drugs acting at histamine H-2 receptors [J]. J Med Chem, 1981, 24: 913-920. (Pubitemid 11015156)
14. Durant GJ, Ganellin CR, Parsons ME. Chemical differentiation of histamine H1-receptor and H2-receptor agonists [J]. J Med Chem, 1975, 18: 905-909.
15. Ash ASF, Schild HO. Receptors mediating some actions of histamine [J]. Br J Pharmacol Chemother, 1966, 27: 427-439.
16. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia [J]. New Engl J Med, 2001, 344: 1031-1037. (Pubitemid 32267972)
17. Zimmermann J, Buchdunger E, Mett H, et al. Phenylamino-pyrimidine (PAP) - derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors [J]. Bioorg Med Chem Lett, 1996, 6: 1221-1226.
18. Zimmermann J, Buchdunger E, Mett H, et al. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives [J]. Bioorg Med Chem Lett, 1997, 7: 187-192. (Pubitemid 27046418)
19. Buchdunger E, Zimmermann J, Mett H, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class [J]. Proc Natl Acad Sci USA, 1995, 92: 2558-2562.
20. Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J]. Nat Rev Drug Discov, 2002, 1: 493-502.
21. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative [J]. Cancer Res, 1996, 56: 100-104.
22. Carroll M, OhnoJones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J]. Blood, 1997, 90: 4947-4952.
23. Sternbach LH. Benzodiazepine story [J]. J Med Chem, 1979, 22: 1-7.
24. Gilman NW, Rosen P, Earley JV, et al. Atropisomers of 1, 4-benzodiazepines - synthesis and resolution of a diazepam-related 1, 4-benzodiazepine [J]. J Am Chem Soc, 1990, 112: 3969-3978. (Pubitemid 20184272)
25. Gilman NW, Rosen P, Earley JV, et al. Atropisomers of 1, 4-benzodiazepines. 2. Synthesis and resolution of imidazo [1, 5-a] [1, 4] benzodiazepines [J]. J Org Chem, 1993, 58: 3285-3298. (Pubitemid 23251194)
26. Barreiro EJ. Strategy of molecular simplification in rational drug design: the discovery of a new cardioactive agent [J]. Quim Nova, 2002, 25: 1172-1180.
27. Silva AG, Zapata-Sudo G, Kummerle AE, et al. Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues [J]. Bioorg Med Chem, 2005, 13: 3431-3437. (Pubitemid 40545797)
28. Kummerle AE, Raimundo JM, Leal CM, et al. Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives [J]. Eur J Med Chem, 2009, 44: 4004-4009.
29. Bocan TMA, Ferguson E, Mcnally W, et al. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, Ci-981 - comparison with selected HMG-CoA reductase inhibitors [J]. Biochim Biophys Acta, 1992, 1123: 133-144.
30. Tse FLS, Smith HT, Ballard FH, et al. Disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in mouse, tat, dog, and monkey [J]. Biopharm Drug Dispos, 1990, 11: 519-531. (Pubitemid 20271440)
31. Shiomi M, Ito T. Effect of cerivastatin sodium, anew inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits [J]. Br J Pharmacol, 1999, 126: 961-968. (Pubitemid 29103712)
32. Watanabe M, Koike H, Ishiba T, et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3, 5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors [J]. Bioorg Med Chem, 1997, 5: 437-444. (Pubitemid 27091350)
33. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase [J]. Science, 2001, 292: 1160-1164. (Pubitemid 32440937)
34. Roth BD, Blankley CJ, Chucholowski AW, et al. Inhibitors of cholesterol-biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]- 2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions 3 and 4 of the pyrrole nucleus [J]. J Med Chem, 1991, 34: 357-366.
35. Esser R, Berry C, Du ZM, et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2 [J]. Br J Pharmacol, 2005, 144: 538-550. (Pubitemid 40349461)
36. Willis JV, Kendall MJ, Flinn RM, et al. Pharmacokinetics of diclofenac sodium following intravenous and oral-administration [J]. Eur J Clin Pharmacol, 1979, 16: 405-410. (Pubitemid 10173752)
37. Correa CM, de Paula AF, da Silva GMS, et al. The molecular basis of COX-2 versus COX-1 selectivity of lumiracoxib by molecular docking studies [J]. Lett Drug Des Discov, 2007, 4: 422-425. (Pubitemid 47607753)
38. Blobaum AL, Marnett LJ. Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib [J]. J Biol Chem, 2007, 282: 16379-16390. (Pubitemid 47100364)
39. Robert A, Nezamis JE, Phillips JP. Inhibition of gastric secretion by prostaglandins [J]. Am J Dig Dis, 1967, 12: 1073-1076.
40. Collins PW. Development and therapeutic role of synthetic prostaglandins in peptic-ulcer disease [J]. J Med Chem, 1986, 29: 437-443. (Pubitemid 16034756)
41. Hammes-Schiffer S, Benkovic SJ. Relating protein motion to catalysis [J]. Annu Rev Biochem, 2006, 75: 519-541. (Pubitemid 44118042)
42. Robert A, Schultz JR, Nezamis JE, et al. Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2-intravenous, oral and intrajejunal administration [J]. Gastroenterology, 1976, 70: 359-370.
43. Dammann HG, Dreyer M, Walter TA, et al. Nocloprost, a novel prostanglandin E2 analog: significant reduction of aspirin induced grastrointestinal lesions in man [J]. Prog Clin Biol Res, 1987, 242: 295-298.
44. Beck G, Bartmann W, Lerch U, et al. Antihypertensive activity of 16, 16-dimethyl-oxa-alkyl-prostaglandins of the PGA2, PGE2 and trans-delta 2-11-deoxy-PGE1 series: structure-activity relationships [J]. Prostaglandins, 1980, 20: 153-69. (Pubitemid 10031272)
45. Smith CJ, Ali A, Hammond ML, et al. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib [J]. J Med Chem, 2011, 54: 4880-4895.
46. Thompson CF, Ali A, Quraishi N, et al. Discovery of substituted biphenyl oxazolidinone inhibitors of cholesteryl ester transfer protein [J]. ACS Med Chem Lett, 2011, 2: 424-427.
47. Lessard E, Fortin A, Belanger PM, et al. Role of CYP2D6 in the N-hydroxylation of procainamide [J]. Pharmacogenetics, 1997, 7: 381-390. (Pubitemid 27427548)
48. Ruetsch YA, Boni T, Borgeat A. From cocaine to ropivacaine: the history of local anesthetic drugs [J]. Curr Top Med Chem, 2001, 1: 175-182.
49. Williams FM. Serum enzymes of drug-metabolism [J]. Pharmacol Ther, 1987, 34: 99-109.
50. Hondeghem LM, Katzung BG. Antiarrhythmic agents - the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs [J]. Annu Rev Pharmacol, 1984, 24: 387-423. (Pubitemid 14129541)
51. Morady F, Dicarlo LA, Baerman JM, et al. Rate-dependent effects of intravenous lidocaine, procainamide and amiodarone on intraventricular- conduction [J]. J Am Coll Cardiol, 1985, 6: 179-185. (Pubitemid 15069260)
52. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib) [J]. J Med Chem, 1997, 40: 1347-1365. (Pubitemid 27198082)
53. Meunier B, de Visser SP, Shaik S. Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes [J]. Chem Rev, 2004, 104: 3947-3980.
54. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans [J]. Curr Drug Metab, 2002, 3: 561-597. (Pubitemid 35331660)
55. Shi SJ, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors [J]. Eur J Clin Pharmacol, 2008, 64: 233-252.
56. Lombardi JG, Wiseman EH. Sudoxicam and related N-heterocyclic carboxamides of 4-hydroxy-2H-1, 2-benzothiazine 1, 1-dioxide - potent nonsteroidal antiinflammatory agents [J]. J Med Chem, 1972, 15: 848-849.
57. Obach RS, Kalgutkar AS, Ryder TF, et al. In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam [J]. Chem Res Toxicol, 2008, 21: 1890-1899.
58. Lazer ES, Miao CK, Cywin CL, et al. Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity [J]. J Med Chem, 1997, 40: 980-989. (Pubitemid 27131629)
59. DiPasquale G, Rassaert CL, Richter RS, et al. The antiinflammatory effects of 4-hydroxy-2-methyl-3-phenylcarbamoyl-2H-1, 2-benzothiazine-1, 1-dioxide (W7477) [J]. Arch Int Pharmacodyn Ther, 1973, 203: 92-100.
60. Talley JJ, Brown DL, Carter JS, et al. 4-[5-methyl-3-phenylisoxazol-4-yl] -benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2 [J]. J Med Chem, 2000, 43: 775-777. (Pubitemid 30152286)
61. Bartlett RR, Dimitrijevic M, Mattar T, et al. Leflunomide (Hwa-486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection [J]. Agents Actions, 1991, 32: 10-21.
62. Davis JP, Cain GA, Pitts WJ, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase [J]. Biochemistry (US), 1996, 35: 1270-1273. (Pubitemid 26050790)
63. Kalgutkar AS, Nguyen HT, Vaz ADN, et al. In vitro metabolism studies on the isoxazole ring scission in the antiinflammatory agent leflunomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes [J]. Drug Metab Dispos, 2003, 31: 1240-1250. (Pubitemid 37152975)
64. Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine, a novel atypical antipsychotic agent [J]. J Pharmacol Exp Ther, 1992, 262: 545-551.
65. Chakrabarti JK, Horsman L, Hotten TM, et al. 4-Piperazinyl-10H-thieno [2, 3-b] [1, 5] benzodiazepines as potential neuroleptics [J]. J Med Chem, 1980, 23: 878-884. (Pubitemid 10091531)
66. Fuller RW, Snoddy HD. Neuroendocrine evidence for antagonism of serotonin and dopamine-receptors by olanzapine (LY170053), an antipsychotic drug candidate [J]. Res Commun Chem Pathol Pharmacol, 1992, 77: 87-93.
67. Verma U, Sharma R, Gupta P, et al. New uses for old drugs: novel therapeutic options [J]. Indian J Pharmacol, 2005, 37: 279-287. (Pubitemid 41434082)
68. Wermuth CG, Bourguignon JJ, Hoffmann R, et al. Sr-46559-a and related aminopyridazines are potent muscarinic agonists with no cholinergic syndrome [J]. Bioorg Med Chem Lett, 1992, 2: 833-838.
69. Kan JP, Steinberg R, Ourydonat F, et al. Sr-46559a - a novel and potent muscarinic compound with no cholinergic syndrome [J]. Psychopharmacology, 1993, 112: 219-227. (Pubitemid 23278282)